<DOC>
	<DOC>NCT01163396</DOC>
	<brief_summary>This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metastatic colorectal cancer.</brief_summary>
	<brief_title>First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirmed colorectal adenocarcinoma Unresectable and measurable metastatic disease (RECIST criteria) Male or female, aged &gt; 18 years and ≤ 75 years ECOG Performance Status (PS) &lt; 2 if aged &lt; 71 years ECOG PS = 0 if aged 7175 years Life expectancy of more than 3 months Adequate haematological function: ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, Hb ≥ 9 g/dL INR ≤ 1.5 and aPTT ≤ 1.5 x ULN within 7 days prior to starting study treatment Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases &lt; 5 x ULN) Serum Creatinine ≤ 1.5 x ULN Urine dipstick for proteinuria &lt; 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse At least 6 weeks from prior radiotherapy and 4 weeks from surgery Prior palliative chemotherapy Prior treatment with bevacizumab Bowel obstruction (or subobstruction) History of inflammatory enteropathy or extensive intestinal resection (&gt; hemicolectomy or extensive small intestine resection with chronic diarrhea) Symptomatic peripheral neuropathy &gt; 2 grade NCICCTG criteria Presence or history of CNS metastasis Active uncontrolled infections Active disseminated intravascular coagulation Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment, or anticipation of the need for major surgery during the course of the study Central Venous Access Device (CVAD) for chemotherapy administration inserted within 2 days prior to study treatment start Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix Clinically significant cardiovascular disease, for example cerebrovascular accidents (CVA) (≤ 6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia Uncontrolled hypertension 24hour urine protein &gt; 1 g if dipstick &gt; 2+ History of thromboembolic or hemorrhagic events within 6 months prior to treatment Evidence of bleeding diathesis or coagulopathy Serious, non healing wound/ulcer or serious bone fracture No therapeutic anticoagulation or antiplatelet agents or NSAID with antiplatelet activity (aspirin ≤ 325 mg/day allowed) Pregnancy or lactation Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>